Buying Encycle Gives Zealand Its First External Asset
Zealand Also Gains Access To Encycle’s Peptide Screening Library
Acquiring Encycle Therapeutics brings Zealand Pharma a promising IBD asset and expands the breadth of its peptide discovery platform.
You may also be interested in...
Takeda has won EU approval for an injectable version of Entyvio to treat ulcerative colitis or Crohn’s disease, in contrast to the FDA’s rejection in December.
Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.
Created when BetterLife bought Altum at end-July, the merged entity will now focus on advancing the acquired group’s lead asset, an inhaled form of its patented interferon a2b product, as an early treatment for COVID-19.